Umbrella Review on Non-Statin Lipid-Lowering Therapy.
Semira Abdi BeshirNadia HussainAsim Ahmed ElnorAmira S A SaidPublished in: Journal of cardiovascular pharmacology and therapeutics (2021)
Despite cost limitations, the uptake of PCSK9 inhibitors is increasing. Approval of bempedoic acid alone or in combination with ezetimibe has provided additional oral lipid-lowering drug alternatives to ezetimibe. Various lipid-lowering drug targets are under investigation.